Business Context and Reporting Period
Company: NERVGEN PHARMA CORP.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: July 2, 2026
Headquarters: Vancouver, British Columbia, Canada
This filing serves as a report of a material event rather than a periodic financial statement. It incorporates by reference a Sales Agreement dated July 2, 2026, between NervGen Pharma Corp. and Leerink Partners LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate agreement and does not contain financial performance data for the period.
Material Changes
Entry into Sales Agreement: The company entered into a Sales Agreement with Leerink Partners LLC on July 2, 2026. This agreement is filed as Exhibit 99.1 and is incorporated by reference into the company's Registration Statements on Form F-10 and Form S-8.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard incorporation by reference language. The primary focus is the execution of the sales agreement.
Investor Verification Checklist
- Review the full text of the Sales Agreement (Exhibit 99.1) to understand the terms of the arrangement with Leerink Partners LLC.
- Verify the impact of this agreement on the company's outstanding Registration Statements (Form F-10 and Form S-8).
- Check subsequent filings for any financial updates or changes in capital structure resulting from this agreement.